Connect with us

Technology

Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market Demand

Published

on

A recent National Pet Owners Survey demonstrates a significant addressable market for Innocan’s veterinary product

HERZLIYA, Israel and CALGARY, AB, Nov. 11, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, announced that it has taken the strategic decision to focus its development resources on advancing its groundbreaking Liposome Platform Technology-Cannabidiol (LPT-CBD), a monthly injectable treatment for chronic pain in both animals and humans. This decision follows encouraging progress with the U.S. Food and Drug Administration (FDA).

 

 

Innocan has received FDA support to advance its LPT-CBD platform for human use under the 505(b)(2) abbreviated pathway, offering a quicker route to commercial approval. The FDA has also aligned on Innocan’s non-clinical development plan and Phase I clinical study design for the LPT-CBD’s Investigational New Drug (IND) filing, moving the Company closer to an accelerated approval process. Furthermore, it is noted that Innocan has made strong progress with the FDA’s Center for Veterinary Medicine (CVM) with the issuance of an Investigational New Animal Drug (INAD) designation in July.

Given recent U.S. Pet industry reports and data released by the American Pet Products Association (APPA) and the National Pet Owners Survey*, Innocan recognizes significant market potential for an injectable treatment for chronic pain in animals:

66% of U.S. households – 87 million homes – own one or more pets, including 58 million with dogs and 40 million with cats.In 2024, U.S. pet industry expenditures are projected to reach US $156 billion, up from USD $147 billion in 2023, with USD $39 billion anticipated for pharmaceutical drugs and veterinary care.

This new data represents a significantly large and growing market for effective veterinary health products like LPT-CBD, Innocan’s monthly injectable drug product. Innocan’s unique technology is comprised of liposomes loaded with CBD for the treatment of chronic pain. LPT-CBD has demonstrated promising results in multiple animal model tests, as previously reported, providing extended pharmacokinetic benefits and effective pain relief lasting up to four weeks.

Following the positive response of the FDA regarding the LPT-CBT product reported in September 2024, as well as the continued progress of the LPT-CBD project and significant addressable market potential for LPT-CBD, Innocan has decided to shift its focus and resources in its pharmaceutical division to the LPT-CBD project, thereby sunsetting its Cannabinoid-Loaded Exosome (CLX) project conducted with Ramot of Tel Aviv University (Ramot) under Prof. Daniel Offen. A suitable notice of termination of its sponsored research agreement dated April 17, 2020 and its research and funding agreement with Ramot dated December 6, 2021 has been sent, concluding this collaboration.

“The latest pet industry reports show that the market potential of the LPT-CBD products in veterinary health is clearly significant,” commented Iris Bincovich, CEO of Innocan. “Our commitment to pioneering solutions for chronic pain in animals aligns with the growing need for effective, compassionate care. By dedicating increased resources to this market, we can expedite our path to market for LPT-CBD and meet the demands of a dynamic and expanding pet care industry.”

* https://www.marketwatch.com/guides/pet-insurance/pet-ownership-statistics/

About Innocan Pharma:

Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.

For more information: www.innocanpharma.com

Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/innocan-to-direct-full-focus-on-following-positive-fda-engagement-and-significant-potential-market-demand-302301266.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

The Denver Post Names Luminate Bank the #1 Large Top Workplace in Colorado for 2026

Published

on

By

MINNEAPOLIS, May 13, 2026 /PRNewswire/ — Luminate Bank® earned the #1 ranking among large companies in The Denver Post’s Colorado Top Workplaces 2026 awards. The company also received the Special Award for Appreciation, recognizing its culture of employee support and recognition. This distinction is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage LLC. The confidential survey uniquely measures the employee experience and its component themes, including that employees feel Respected & Supported, Enabled to Grow, and Empowered to Execute, to name a few.

“Being named a Top Workplace is incredibly meaningful because it comes directly from the individuals who choose to grow their careers with us and show up every day with purpose and conviction. They are the foundation of our success,” said Eric Lovins, President of Mortgage Lending at Luminate Bank. “We don’t take the responsibility of earning their trust lightly, and we remain committed to creating an environment where they can thrive, succeed, and feel proud of the work they do.”

Luminate Bank traces its roots to 1937, when it first opened as Equity Bank. In 2020, the organization was acquired and reintroduced as Luminate Bank and Luminate Home Loans, reflecting a renewed commitment to guiding customers through complex financial moments with clarity and care. In 2025, Luminate Home Loans and Luminate Bank unified under one brand, combining full-service banking with a strong mortgage platform to expand offerings and better serve customers. Today, Luminate Bank’s team of more than 700 professionals nationwide continues to focus on relationship-based banking paired with digital innovation, supporting responsible growth and long-term customer success.

“Earning a Top Workplaces award is a badge of honor for companies, especially because it comes authentically from their employees,” said Eric Rubino, Energage CEO. “That’s something to be proud of. In today’s market, leaders must ensure they’re allowing employees to have a voice and be heard. That’s paramount. Top Workplaces do this, and it pays dividends.”

About Luminate Bank® — At Luminate Bank, We Open Doors—empowering individuals and families to achieve their financial dreams through personalized service and innovative digital solutions. As a nationwide bank headquartered in Minneapolis, Minnesota, we are committed to helping our clients meet their financial goals with a blend of modern technology, traditional values, and the trusted guidance of experienced professionals. Known for our exceptional commitment to customers, we take pride in delivering a seamless, supportive experience for every step of the journey. Our dedicated mortgage division has branches and a team of loan originators across the US, making expert home financing solutions accessible to communities nationwide.

Luminate Bank is committed to safeguarding your money and accounts with FDIC insurance coverage up to applicable limits. Learn more about how we can open doors for you at www.luminate.bank, follow us on Instagram, LinkedIn, and Facebook, or call (952) 939-7200.

ABOUT ENERGAGE
Making the world a better place to work together.™
Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 20 years of culture research and the results from 30 million employees surveyed across more than 80,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit energage.com or topworkplaces.com.

Media Contact
Debbie Schwake, CMO
debbie.schwake@luminate.bank
952-698-3300

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-denver-post-names-luminate-bank-the-1-large-top-workplace-in-colorado-for-2026-302771529.html

SOURCE Luminate Bank

Continue Reading

Technology

InfoSight Launches AI-Enabled Purple Team SOCaaS: Machine-Speed Defense, Human-Led Control

Published

on

By

Purple SOC Unifies Offensive Testing, Defensive Monitoring, and AI-Driven Detection Engineering Into a Single Human-Led Security Program

MIAMI, May 13, 2026 /PRNewswire/ — InfoSight today announced the general availability of its AI-Enabled Purple Team Security Operations Center as a Service (SOCaaS)—a managed security solution that combines AI-driven attack path intelligence with human-led security governance. The service redefines how organizations detect, validate, and respond to modern cyber threats by unifying offensive adversary emulation and defensive monitoring into a single, continuously operating program.

AI-Enabled Purple SOC: Offensive Testing, Defensive Monitoring & Detection Engineering in One Human-Led Security Program

Modern enterprises face a growing mismatch between attacker speed and defender capability. AI-driven attack tools now operate at scale—testing controls, chaining vulnerabilities, and adapting faster than traditional SOC workflows can respond. Meanwhile, many Security Operations Centers (SOC) remain constrained by human-speed processes, where alert queues backlog, tickets accumulate, and threats progress before action is taken.

The challenge is no longer visibility—it is speed, correlation, and execution.

InfoSight’s Purple Team SOCaaS addresses this gap by delivering continuous threat exposure management across the full attack lifecycle. Rather than reacting to alerts alone, the AI-enabled experts continuously hunt for Advanced Persistent Threats (APT) and indicators of compromise (IOC)while decoding real-time threat signals to anticipate adversary behavior before incidents occur.

Core Capabilities

AI-driven attack path correlation across identity, cloud, and critical systemsAdversary emulation aligned to real-world MITRE ATT&CK techniques TTPsReal-time validation of SIEM, XDR, and EDR detections and response workflowsDynamic feedback loops that continuously update rules, telemetry, and playbooksHuman-led oversight for threat modeling, risk acceptance, and executive reporting

By fusing traditionally siloed red team and blue team functions with AI enablement, Purple SOCaaS creates a continuously learning security program. When detection gaps are identified, rules, telemetry configurations, and response playbooks are refined continuously instead of waiting for scheduled review cycles.

When analysts engage, alerts are already enriched, correlated, and prioritized. Evidence is pre-assembled across identity, endpoint, network, and cloud telemetry, allowing security teams to shift focus from manual triage to higher-value decisions such as determining scope, assessing control weaknesses, and directing response actions.

Purple SOCaaS delivers measurable business outcomes, including:

Reduced Mean Time to Detect (MTTD) and Mean Time to Respond (MTTR)Expanded detection coverage across high-risk attack vectorsReduced blast radius through continuous control validationStrengthened identity and privileged access controls based on proven adversary pathwaysBoard-level reporting tied to quantified exposure reduction over time

InfoSight’s Purple SOCaaS is delivered through a structured 30–60-day onboarding and launch program, followed by continuous validation cycles.

“Bad actors can operate at machine speed on a scale like never before, so organizations no longer have the luxury of reactive 8-5 security operations. Adversaries operate continuously, so defenses must too. Purple SOCaaS allows security teams to go on the offense and anticipate threats bases upon intent signals to stay ahead of modern threats. Attacks are running at machine speed so modern SOC operations must match the new pace. — Tom Garcia, President & CEO, InfoSight

InfoSight’s AI-Enabled Purple Team SOCaaS is available immediately for enterprise and mid-market organizations. Organizations can request an executive overview or technical brief by contacting InfoSight directly.

About InfoSight

InfoSight, Inc. is a cybersecurity services firm helping organizations reduce cyber risk across healthcare, financial services, manufacturing, energy, and government sectors. Founded in 1998, InfoSight delivers advanced security operations, risk management, and compliance solutions that help organizations strengthen defenses, reduce exposure, and protect critical systems and digital assets.

Media Contact:
Yendi Valdes
Marketing Director, InfoSight
Yendi.Valdes@infosightinc.com 
1-305-828-1003

View original content to download multimedia:https://www.prnewswire.com/news-releases/infosight-launches-ai-enabled-purple-team-socaas-machine-speed-defense-human-led-control-302771525.html

SOURCE InfoSight, Inc.

Continue Reading

Technology

Tuya Inc. to Hold Annual General Meeting on June 18, 2026

Published

on

By

SANTA CLARA, Calif., May 13, 2026 /PRNewswire/ — Tuya Inc. (“Tuya” or the “Company”) (NYSE: TUYA; HKEX: 2391), a global leading AI cloud platform service provider, today announced that it will hold an annual general meeting of the Company’s shareholders (the “AGM”) at 2:00 p.m. (Hong Kong time) on Thursday, June 18, 2026 at Huace Center, Building A, 3/F VVIP room, Xihu District, Hangzhou City, Zhejiang Province, 310012, China, for the purposes of considering and, if thought fit, passing each of the Proposed Resolutions as defined and set forth in the notice of the AGM (the “AGM Notice”). The AGM Notice and the form of proxy for the AGM are available on the Company’s website at ir.tuya.com. The board of directors of the Company fully supports the Proposed Resolutions and recommends that shareholders and holders of American depositary shares (“ADSs”) vote in favor of the Proposed Resolutions.

Holders of record of the Company’s ordinary shares as of the close of business on May 22, 2026 (Hong Kong time) are entitled to receive notice of, and to attend and vote at, the AGM or any adjournment or postponement thereof. Holders of record of ADSs as of the close of business on May 22, 2026 (New York time) who wish to exercise their voting rights for the ADSs underlying Class A ordinary shares must give voting instructions directly to The Bank of New York Mellon, the depositary of the ADSs, if ADSs are held directly by holders on the books and records of The Bank of New York Mellon or indirectly through a bank, brokerage or other securities intermediary if the ADSs are held by any of them on behalf of holders.

The Company has filed its annual report on Form 20-F, including its audited financial statements, for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the “SEC”). The Company’s annual report on Form 20-F can be accessed on the Company’s website at ir.tuya.com and on the SEC’s website at http://www.sec.gov.

About Tuya Inc.

Tuya Inc. (NYSE: TUYA; HKEX: 2391) is a global leading AI cloud platform service provider with a mission to build an AI developer ecosystem and enable everything to be smart. Tuya has pioneered a purpose-built AI cloud platform with cloud and generative AI capabilities that delivers a full suite of offerings, including Platform-as-a-Service, or PaaS, AI application & others and Smart home & robot products for developers of smart device, commercial applications, and industries. Through its AI developer platform, Tuya has activated a vibrant global developer community of brands, OEMs, AI agents, system integrators and independent software vendors to collectively strive for smart solutions ecosystem embodying the principles of green and low-carbon, security, high efficiency, agility, and openness.

Investor Relations Contact

Tuya Inc.
Investor Relations
Email: ir@tuya.com

HL Strategy
Haiyan LI-LABBE
Email: hl@hl-strategy.com

Piacente Financial Communications
China Tel: +86-10-6508-0677
U.S. Tel: +1-212-481-2050
Email: tuya@thepiacentegroup.com

View original content:https://www.prnewswire.com/news-releases/tuya-inc-to-hold-annual-general-meeting-on-june-18-2026-302771184.html

SOURCE Tuya Inc.

Continue Reading

Trending